Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo
Angewandte Chemie International Edition · 16.01.2026 · 65 (3)
DOI: 10.1002/anie.202518249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 17.11.2025. Verfasst von Chen He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu, 211198, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Deubiquitinating Enzymes, Small Molecule Libraries, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Wild‐type p53 is a tumor suppressor protein that is crucial in various pathological processes. The predominant strategy for p53 Y220C mutant involves binding reactivators to mutation‐induced pocket to stabilize the protein thermally and restore wild‐type structure. However, the corrected p53 Y220C remains vulnerable to ubiquitination, reducing protein levels and impairing function. Herein, we report the development of p53 Y220C‐specific deubiquitinase‐targeting chimeras (DUBTACs)—bifunctional small molecules concurrently recruiting both p53 Y220C and the deubiquitinase OTUB1. The most potent compound, A1 , effectively restored wild‐type conformation and potently removed ubiquitin. Furthermore, A1 demonstrated superior efficacy in inducing apoptosis in p53 Y220C‐mutant Huh7 cells and achieved a 61.06% reduction in tumor weight in Huh7 xenograft model. Our results demonstrated the viability of the DUBTAC strategy for p53 Y220C, successfully re‐establishing conformation and promoting deubiquitination. More importantly, this study provides the first proof‐of‐concept for DUBTAC application in vivo, establishing targeted deubiquitination as a therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu, 211198, China.
- School of Life Science and Technology, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu, 211198, China.
ORCID-Profile: Jinyi Xu, Hong Yao, Shengtao Xu
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- partner repository with the dataset identifier
Zitieren
APA
He, C., Li, J., Cui, C., Xie, J., Feng, J., Zhang, B., Huang, X., Ma, R., Zheng, L., Xu, J., Yao, H., & Xu, S. (2026). Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo. Angewandte Chemie International Edition, 65(3). https://doi.org/10.1002/anie.202518249
Vancouver
He C, Li J, Cui C, Xie J, Feng J, Zhang B, et al. Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo. Angewandte Chemie International Edition. 2026;65(3). doi:10.1002/anie.202518249
BibTeX
@article{He2026,
author = {He, Chen and Li, Junda and Cui, Chenxi and Xie, Jia and Feng, Jiajie and Zhang, Baixue and Huang, Xingting and Ma, Ruoping and Zheng, Lufeng and Xu, Jinyi and Yao, Hong and Xu, Shengtao},
title = {Construction of Small‐Molecule Deubiquitinase‐Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo},
journal = {Angewandte Chemie International Edition},
year = {2026},
volume = {65},
number = {3},
doi = {10.1002/anie.202518249}
}
EUVIMED